APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Cognitive and Memory Enhancer Drugs

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Cognitive and Memory Enhancer Drugs Market Outlook and Growth Opportunities 2026

Report ID 173979320422 December 2025192 pages

Choose your research edition.

Industry ResearchCognitive and Memory Enhancer Drugs Industry Research Report 2026117 pages · $2,950 USDIndustry Growth & TrendsGlobal Cognitive and Memory Enhancer Drugs Industry Growth and Trends Forecast to 2032104 pages · $3,450 USDMarket StructureGlobal Cognitive and Memory Enhancer Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Cognitive and Memory Enhancer Drugs Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Cognitive and Memory Enhancer Drugs Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

The global Cognitive and Memory Enhancer Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Cognitive and Memory Enhancer Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Cognitive and Memory Enhancer Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Cognitive and Memory Enhancer Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Cognitive and Memory Enhancer Drugs market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Cognitive and Memory Enhancer Drugs market include Takeda Pharmaceutical Company Limited, Takeda, Eisai Co, Johnson & Johnson, Novartis, Pfizer, Ceretropic, Cephalon and AlternaScript, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Cognitive and Memory Enhancer Drugs market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Cognitive and Memory Enhancer Drugs and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Cognitive and Memory Enhancer Drugs revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Cognitive and Memory Enhancer Drugs market.

Cognitive and Memory Enhancer Drugs Segment by Company

Takeda Pharmaceutical Company Limited

Takeda

Eisai Co

Johnson & Johnson

Novartis

Pfizer

Ceretropic

Cephalon

AlternaScript

Allergan

Cognitive and Memory Enhancer Drugs Segment by Type

Namenda

Provigil

Ritalin

Razadyne

Aricept

Exelon

Adderall

Others

Cognitive and Memory Enhancer Drugs Segment by Application

Disease Treatment

Academic Performance

Athletic Performance

Others

Cognitive and Memory Enhancer Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Cognitive and Memory Enhancer Drugs status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Cognitive and Memory Enhancer Drugs key companies, revenue, market share, and recent developments.

3. To split the Cognitive and Memory Enhancer Drugs breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Cognitive and Memory Enhancer Drugs market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Cognitive and Memory Enhancer Drugs significant trends, drivers, influence factors in global and regions.

6. To analyze Cognitive and Memory Enhancer Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Cognitive and Memory Enhancer Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Cognitive and Memory Enhancer Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Cognitive and Memory Enhancer Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Cognitive and Memory Enhancer Drugs industry.

Chapter 3: Detailed analysis of Cognitive and Memory Enhancer Drugs company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Cognitive and Memory Enhancer Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Cognitive and Memory Enhancer Drugs in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Cognitive and Memory Enhancer Drugs Industry Trends Table 2. Cognitive and Memory Enhancer Drugs Industry Drivers Table 3. Cognitive and Memory Enhancer Drugs Industry Opportunities and Challenges Table 4. Cognitive and Memory Enhancer Drugs Industry Restraints Table 5. Global Cognitive and Memory Enhancer Drugs Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Cognitive and Memory Enhancer Drugs Revenue Share by Company (2021-2026) Table 7. Global Cognitive and Memory Enhancer Drugs Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Cognitive and Memory Enhancer Drugs Key Company Manufacturing Base & Headquarters Table 9. Global Cognitive and Memory Enhancer Drugs Company, Product Type & Application Table 10. Global Cognitive and Memory Enhancer Drugs Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Cognitive and Memory Enhancer Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Namenda Table 15. Significant Companies of Provigil Table 16. Significant Companies of Ritalin Table 17. Significant Companies of Razadyne Table 18. Significant Companies of Aricept Table 19. Significant Companies of Exelon Table 20. Significant Companies of Adderall Table 21. Significant Companies of Others Table 22. Global Cognitive and Memory Enhancer Drugs Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 23. Global Cognitive and Memory Enhancer Drugs Sales Value by Type (2021-2026) & (US$ Million) Table 24. Global Cognitive and Memory Enhancer Drugs Sales Value by Type (2027-2032) & (US$ Million) Table 25. Global Cognitive and Memory Enhancer Drugs Sales Value Share by Type (2021-2026) Table 26. Global Cognitive and Memory Enhancer Drugs Sales Value Share by Type (2027-2032) Table 27. Significant Companies of Disease Treatment Table 28. Significant Companies of Academic Performance Table 29. Significant Companies of Athletic Performance Table 30. Significant Companies of Others Table 31. Global Cognitive and Memory Enhancer Drugs Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Cognitive and Memory Enhancer Drugs Sales Value by Application (2021-2026) & (US$ Million) Table 33. Global Cognitive and Memory Enhancer Drugs Sales Value by Application (2027-2032) & (US$ Million) Table 34. Global Cognitive and Memory Enhancer Drugs Sales Value Share by Application (2021-2026) Table 35. Global Cognitive and Memory Enhancer Drugs Sales Value Share by Application (2027-2032) Table 36. Global Cognitive and Memory Enhancer Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Cognitive and Memory Enhancer Drugs Sales Value by Region (2021-2026) & (US$ Million) Table 38. Global Cognitive and Memory Enhancer Drugs Sales Value Share by Region (2021-2026) Table 39. Global Cognitive and Memory Enhancer Drugs Sales Value by Region (2027-2032) & (US$ Million) Table 40. Global Cognitive and Memory Enhancer Drugs Sales Value Share by Region (2027-2032) Table 41. Global Cognitive and Memory Enhancer Drugs Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 42. Global Cognitive and Memory Enhancer Drugs Sales Value by Country (2021-2026) & (US$ Million) Table 43. Global Cognitive and Memory Enhancer Drugs Sales Value Market Share by Country (2021-2026) Table 44. Global Cognitive and Memory Enhancer Drugs Sales Value by Country (2027-2032) & (US$ Million) Table 45. Global Cognitive and Memory Enhancer Drugs Sales Value Market Share by Country (2027-2032) Table 46. Takeda Pharmaceutical Company Limited Company Information Table 47. Takeda Pharmaceutical Company Limited Business Overview Table 48. Takeda Pharmaceutical Company Limited Cognitive and Memory Enhancer Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 49. Takeda Pharmaceutical Company Limited Cognitive and Memory Enhancer Drugs Product Portfolio Table 50. Takeda Pharmaceutical Company Limited Recent Development Table 51. Takeda Company Information Table 52. Takeda Business Overview Table 53. Takeda Cognitive and Memory Enhancer Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 54. Takeda Cognitive and Memory Enhancer Drugs Product Portfolio Table 55. Takeda Recent Development Table 56. Eisai Co Company Information Table 57. Eisai Co Business Overview Table 58. Eisai Co Cognitive and Memory Enhancer Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 59. Eisai Co Cognitive and Memory Enhancer Drugs Product Portfolio Table 60. Eisai Co Recent Development Table 61. Johnson & Johnson Company Information Table 62. Johnson & Johnson Business Overview Table 63. Johnson & Johnson Cognitive and Memory Enhancer Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 64. Johnson & Johnson Cognitive and Memory Enhancer Drugs Product Portfolio Table 65. Johnson & Johnson Recent Development Table 66. Novartis Company Information Table 67. Novartis Business Overview Table 68. Novartis Cognitive and Memory Enhancer Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. Novartis Cognitive and Memory Enhancer Drugs Product Portfolio Table 70. Novartis Recent Development Table 71. Pfizer Company Information Table 72. Pfizer Business Overview Table 73. Pfizer Cognitive and Memory Enhancer Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. Pfizer Cognitive and Memory Enhancer Drugs Product Portfolio Table 75. Pfizer Recent Development Table 76. Ceretropic Company Information Table 77. Ceretropic Business Overview Table 78. Ceretropic Cognitive and Memory Enhancer Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. Ceretropic Cognitive and Memory Enhancer Drugs Product Portfolio Table 80. Ceretropic Recent Development Table 81. Cephalon Company Information Table 82. Cephalon Business Overview Table 83. Cephalon Cognitive and Memory Enhancer Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 84. Cephalon Cognitive and Memory Enhancer Drugs Product Portfolio Table 85. Cephalon Recent Development Table 86. AlternaScript Company Information Table 87. AlternaScript Business Overview Table 88. AlternaScript Cognitive and Memory Enhancer Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 89. AlternaScript Cognitive and Memory Enhancer Drugs Product Portfolio Table 90. AlternaScript Recent Development Table 91. Allergan Company Information Table 92. Allergan Business Overview Table 93. Allergan Cognitive and Memory Enhancer Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 94. Allergan Cognitive and Memory Enhancer Drugs Product Portfolio Table 95. Allergan Recent Development Table 96. Research Programs/Design for This Report Table 97. Authors List of This Report Table 98. Secondary Sources Table 99. Primary Sources List of Figures Figure 1. Cognitive and Memory Enhancer Drugs Product Image Figure 2. Global Cognitive and Memory Enhancer Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Cognitive and Memory Enhancer Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global Cognitive and Memory Enhancer Drugs Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Namenda Image Figure 8. Provigil Image Figure 9. Ritalin Image Figure 10. Razadyne Image Figure 11. Aricept Image Figure 12. Exelon Image Figure 13. Adderall Image Figure 14. Others Image Figure 15. Global Cognitive and Memory Enhancer Drugs Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Cognitive and Memory Enhancer Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Cognitive and Memory Enhancer Drugs Sales Value Share by Type (2021-2032) Figure 18. Disease Treatment Image Figure 19. Academic Performance Image Figure 20. Athletic Performance Image Figure 21. Others Image Figure 22. Global Cognitive and Memory Enhancer Drugs Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global Cognitive and Memory Enhancer Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 24. Global Cognitive and Memory Enhancer Drugs Sales Value Share by Application (2021-2032) Figure 25. Global Cognitive and Memory Enhancer Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 26. Global Cognitive and Memory Enhancer Drugs Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 27. North America Cognitive and Memory Enhancer Drugs Sales Value (2021-2032) & (US$ Million) Figure 28. North America Cognitive and Memory Enhancer Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 29. Europe Cognitive and Memory Enhancer Drugs Sales Value (2021-2032) & (US$ Million) Figure 30. Europe Cognitive and Memory Enhancer Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 31. Asia-Pacific Cognitive and Memory Enhancer Drugs Sales Value (2021-2032) & (US$ Million) Figure 32. Asia-Pacific Cognitive and Memory Enhancer Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 33. South America Cognitive and Memory Enhancer Drugs Sales Value (2021-2032) & (US$ Million) Figure 34. South America Cognitive and Memory Enhancer Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Middle East & Africa Cognitive and Memory Enhancer Drugs Sales Value (2021-2032) & (US$ Million) Figure 36. Middle East & Africa Cognitive and Memory Enhancer Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 37. USA Cognitive and Memory Enhancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 38. USA Cognitive and Memory Enhancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 39. USA Cognitive and Memory Enhancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 40. Canada Cognitive and Memory Enhancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. Canada Cognitive and Memory Enhancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. Canada Cognitive and Memory Enhancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Mexico Cognitive and Memory Enhancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Mexico Cognitive and Memory Enhancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Mexico Cognitive and Memory Enhancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Germany Cognitive and Memory Enhancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Germany Cognitive and Memory Enhancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Germany Cognitive and Memory Enhancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. France Cognitive and Memory Enhancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. France Cognitive and Memory Enhancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. France Cognitive and Memory Enhancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. U.K. Cognitive and Memory Enhancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. U.K. Cognitive and Memory Enhancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. U.K. Cognitive and Memory Enhancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Italy Cognitive and Memory Enhancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Italy Cognitive and Memory Enhancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Italy Cognitive and Memory Enhancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Spain Cognitive and Memory Enhancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Spain Cognitive and Memory Enhancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Spain Cognitive and Memory Enhancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Russia Cognitive and Memory Enhancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Russia Cognitive and Memory Enhancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Russia Cognitive and Memory Enhancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Netherlands Cognitive and Memory Enhancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Netherlands Cognitive and Memory Enhancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Netherlands Cognitive and Memory Enhancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Nordic Countries Cognitive and Memory Enhancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Nordic Countries Cognitive and Memory Enhancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Nordic Countries Cognitive and Memory Enhancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. China Cognitive and Memory Enhancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. China Cognitive and Memory Enhancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. China Cognitive and Memory Enhancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. Japan Cognitive and Memory Enhancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. Japan Cognitive and Memory Enhancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. Japan Cognitive and Memory Enhancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. South Korea Cognitive and Memory Enhancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. South Korea Cognitive and Memory Enhancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. South Korea Cognitive and Memory Enhancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. India Cognitive and Memory Enhancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. India Cognitive and Memory Enhancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. India Cognitive and Memory Enhancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Australia Cognitive and Memory Enhancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Australia Cognitive and Memory Enhancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Australia Cognitive and Memory Enhancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Southeast Asia Cognitive and Memory Enhancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Southeast Asia Cognitive and Memory Enhancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Southeast Asia Cognitive and Memory Enhancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Brazil Cognitive and Memory Enhancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Brazil Cognitive and Memory Enhancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Brazil Cognitive and Memory Enhancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Argentina Cognitive and Memory Enhancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Argentina Cognitive and Memory Enhancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Argentina Cognitive and Memory Enhancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Chile Cognitive and Memory Enhancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Chile Cognitive and Memory Enhancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Chile Cognitive and Memory Enhancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Colombia Cognitive and Memory Enhancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Colombia Cognitive and Memory Enhancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Colombia Cognitive and Memory Enhancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Peru Cognitive and Memory Enhancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Peru Cognitive and Memory Enhancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Peru Cognitive and Memory Enhancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Saudi Arabia Cognitive and Memory Enhancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Saudi Arabia Cognitive and Memory Enhancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Saudi Arabia Cognitive and Memory Enhancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Israel Cognitive and Memory Enhancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Israel Cognitive and Memory Enhancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Israel Cognitive and Memory Enhancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. UAE Cognitive and Memory Enhancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. UAE Cognitive and Memory Enhancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. UAE Cognitive and Memory Enhancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Turkey Cognitive and Memory Enhancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Turkey Cognitive and Memory Enhancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Turkey Cognitive and Memory Enhancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Iran Cognitive and Memory Enhancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Iran Cognitive and Memory Enhancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Iran Cognitive and Memory Enhancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Egypt Cognitive and Memory Enhancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Egypt Cognitive and Memory Enhancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Egypt Cognitive and Memory Enhancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Years Considered Figure 122. Research Process Figure 123. Key Executives Interviewed

Scope & coverage.

Types
  • Namenda
  • Provigil
  • Ritalin
  • Razadyne
  • Aricept
  • Exelon
  • Adderall
  • Others
Applications
  • Disease Treatment
  • Academic Performance
  • Athletic Performance
  • Others
Companies covered
  • Takeda Pharmaceutical Company Limited
  • Takeda
  • Eisai Co
  • Johnson & Johnson
  • Novartis
  • Pfizer
  • Ceretropic
  • Cephalon
  • AlternaScript
  • Allergan

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Cognitive and Memory Enhancer Drugs Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Cognitive and Memory Enhancer Drugs Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Cognitive and Memory Enhancer Drugs Market Dynamics
  1. 2.1 Cognitive and Memory Enhancer Drugs Industry Trends
  2. 2.2 Cognitive and Memory Enhancer Drugs Industry Drivers
  3. 2.3 Cognitive and Memory Enhancer Drugs Industry Opportunities and Challenges
  4. 2.4 Cognitive and Memory Enhancer Drugs Industry Restraints
3 Cognitive and Memory Enhancer Drugs Market by Company
  1. 3.1 Global Cognitive and Memory Enhancer Drugs Company Revenue Ranking in 2025
  2. 3.2 Global Cognitive and Memory Enhancer Drugs Revenue by Company (2021-2026)
  3. 3.3 Global Cognitive and Memory Enhancer Drugs Company Ranking (2024-2026)
  4. 3.4 Global Cognitive and Memory Enhancer Drugs Company Manufacturing Base and Headquarters
  5. 3.5 Global Cognitive and Memory Enhancer Drugs Company Product Type and Application
  6. 3.6 Global Cognitive and Memory Enhancer Drugs Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Cognitive and Memory Enhancer Drugs Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Cognitive and Memory Enhancer Drugs Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Cognitive and Memory Enhancer Drugs Market by Type
  1. 4.1 Cognitive and Memory Enhancer Drugs Type Introduction
  2. 4.1.1 Namenda
  3. 4.1.2 Provigil
  4. 4.1.3 Ritalin
  5. 4.1.4 Razadyne
  6. 4.1.5 Aricept
  7. 4.1.6 Exelon
  8. 4.1.7 Adderall
  9. 4.1.8 Others
  10. 4.2 Global Cognitive and Memory Enhancer Drugs Sales Value by Type
  11. 4.2.1 Global Cognitive and Memory Enhancer Drugs Sales Value by Type (2021 VS 2025 VS 2032)
  12. 4.2.2 Global Cognitive and Memory Enhancer Drugs Sales Value by Type (2021-2032)
  13. 4.2.3 Global Cognitive and Memory Enhancer Drugs Sales Value Share by Type (2021-2032)
5 Cognitive and Memory Enhancer Drugs Market by Application
  1. 5.1 Cognitive and Memory Enhancer Drugs Application Introduction
  2. 5.1.1 Disease Treatment
  3. 5.1.2 Academic Performance
  4. 5.1.3 Athletic Performance
  5. 5.1.4 Others
  6. 5.2 Global Cognitive and Memory Enhancer Drugs Sales Value by Application
  7. 5.2.1 Global Cognitive and Memory Enhancer Drugs Sales Value by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Cognitive and Memory Enhancer Drugs Sales Value by Application (2021-2032)
  9. 5.2.3 Global Cognitive and Memory Enhancer Drugs Sales Value Share by Application (2021-2032)
6 Cognitive and Memory Enhancer Drugs Regional Value Analysis
  1. 6.1 Global Cognitive and Memory Enhancer Drugs Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Cognitive and Memory Enhancer Drugs Sales Value by Region (2021-2032)
  3. 6.2.1 Global Cognitive and Memory Enhancer Drugs Sales Value by Region: 2021-2026
  4. 6.2.2 Global Cognitive and Memory Enhancer Drugs Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Cognitive and Memory Enhancer Drugs Sales Value (2021-2032)
  7. 6.3.2 North America Cognitive and Memory Enhancer Drugs Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Cognitive and Memory Enhancer Drugs Sales Value (2021-2032)
  10. 6.4.2 Europe Cognitive and Memory Enhancer Drugs Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Cognitive and Memory Enhancer Drugs Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Cognitive and Memory Enhancer Drugs Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Cognitive and Memory Enhancer Drugs Sales Value (2021-2032)
  16. 6.6.2 South America Cognitive and Memory Enhancer Drugs Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Cognitive and Memory Enhancer Drugs Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Cognitive and Memory Enhancer Drugs Sales Value Share by Country, 2025 VS 2032
7 Cognitive and Memory Enhancer Drugs Country-level Value Analysis
  1. 7.1 Global Cognitive and Memory Enhancer Drugs Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Cognitive and Memory Enhancer Drugs Sales Value by Country (2021-2032)
  3. 7.2.1 Global Cognitive and Memory Enhancer Drugs Sales Value by Country (2021-2026)
  4. 7.2.2 Global Cognitive and Memory Enhancer Drugs Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Cognitive and Memory Enhancer Drugs Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Cognitive and Memory Enhancer Drugs Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Cognitive and Memory Enhancer Drugs Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Cognitive and Memory Enhancer Drugs Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Cognitive and Memory Enhancer Drugs Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Cognitive and Memory Enhancer Drugs Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Cognitive and Memory Enhancer Drugs Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Cognitive and Memory Enhancer Drugs Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Cognitive and Memory Enhancer Drugs Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Cognitive and Memory Enhancer Drugs Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Cognitive and Memory Enhancer Drugs Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Cognitive and Memory Enhancer Drugs Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Cognitive and Memory Enhancer Drugs Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Cognitive and Memory Enhancer Drugs Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Cognitive and Memory Enhancer Drugs Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Cognitive and Memory Enhancer Drugs Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Cognitive and Memory Enhancer Drugs Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Cognitive and Memory Enhancer Drugs Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Cognitive and Memory Enhancer Drugs Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Cognitive and Memory Enhancer Drugs Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Cognitive and Memory Enhancer Drugs Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Cognitive and Memory Enhancer Drugs Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Cognitive and Memory Enhancer Drugs Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Cognitive and Memory Enhancer Drugs Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Cognitive and Memory Enhancer Drugs Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Cognitive and Memory Enhancer Drugs Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Cognitive and Memory Enhancer Drugs Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Cognitive and Memory Enhancer Drugs Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Cognitive and Memory Enhancer Drugs Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Cognitive and Memory Enhancer Drugs Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Cognitive and Memory Enhancer Drugs Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Cognitive and Memory Enhancer Drugs Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Cognitive and Memory Enhancer Drugs Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Cognitive and Memory Enhancer Drugs Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Cognitive and Memory Enhancer Drugs Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Cognitive and Memory Enhancer Drugs Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Cognitive and Memory Enhancer Drugs Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Cognitive and Memory Enhancer Drugs Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Cognitive and Memory Enhancer Drugs Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Cognitive and Memory Enhancer Drugs Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Cognitive and Memory Enhancer Drugs Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Cognitive and Memory Enhancer Drugs Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Cognitive and Memory Enhancer Drugs Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Cognitive and Memory Enhancer Drugs Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Cognitive and Memory Enhancer Drugs Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Cognitive and Memory Enhancer Drugs Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Cognitive and Memory Enhancer Drugs Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Cognitive and Memory Enhancer Drugs Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Cognitive and Memory Enhancer Drugs Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Cognitive and Memory Enhancer Drugs Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Cognitive and Memory Enhancer Drugs Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Cognitive and Memory Enhancer Drugs Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Cognitive and Memory Enhancer Drugs Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Cognitive and Memory Enhancer Drugs Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Cognitive and Memory Enhancer Drugs Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Cognitive and Memory Enhancer Drugs Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Cognitive and Memory Enhancer Drugs Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Cognitive and Memory Enhancer Drugs Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Cognitive and Memory Enhancer Drugs Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Cognitive and Memory Enhancer Drugs Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Cognitive and Memory Enhancer Drugs Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Cognitive and Memory Enhancer Drugs Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Cognitive and Memory Enhancer Drugs Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Cognitive and Memory Enhancer Drugs Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Cognitive and Memory Enhancer Drugs Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Cognitive and Memory Enhancer Drugs Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Cognitive and Memory Enhancer Drugs Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Cognitive and Memory Enhancer Drugs Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Cognitive and Memory Enhancer Drugs Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Cognitive and Memory Enhancer Drugs Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Cognitive and Memory Enhancer Drugs Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Cognitive and Memory Enhancer Drugs Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Cognitive and Memory Enhancer Drugs Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Cognitive and Memory Enhancer Drugs Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Cognitive and Memory Enhancer Drugs Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Cognitive and Memory Enhancer Drugs Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Cognitive and Memory Enhancer Drugs Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Cognitive and Memory Enhancer Drugs Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Cognitive and Memory Enhancer Drugs Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Cognitive and Memory Enhancer Drugs Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Cognitive and Memory Enhancer Drugs Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Cognitive and Memory Enhancer Drugs Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Cognitive and Memory Enhancer Drugs Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Cognitive and Memory Enhancer Drugs Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Takeda Pharmaceutical Company Limited
  2. 8.1.1 Takeda Pharmaceutical Company Limited Company Information
  3. 8.1.2 Takeda Pharmaceutical Company Limited Business Overview
  4. 8.1.3 Takeda Pharmaceutical Company Limited Cognitive and Memory Enhancer Drugs Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Takeda Pharmaceutical Company Limited Cognitive and Memory Enhancer Drugs Product Portfolio
  6. 8.1.5 Takeda Pharmaceutical Company Limited Recent Developments
  7. 8.2 Takeda
  8. 8.2.1 Takeda Company Information
  9. 8.2.2 Takeda Business Overview
  10. 8.2.3 Takeda Cognitive and Memory Enhancer Drugs Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Takeda Cognitive and Memory Enhancer Drugs Product Portfolio
  12. 8.2.5 Takeda Recent Developments
  13. 8.3 Eisai Co
  14. 8.3.1 Eisai Co Company Information
  15. 8.3.2 Eisai Co Business Overview
  16. 8.3.3 Eisai Co Cognitive and Memory Enhancer Drugs Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Eisai Co Cognitive and Memory Enhancer Drugs Product Portfolio
  18. 8.3.5 Eisai Co Recent Developments
  19. 8.4 Johnson & Johnson
  20. 8.4.1 Johnson & Johnson Company Information
  21. 8.4.2 Johnson & Johnson Business Overview
  22. 8.4.3 Johnson & Johnson Cognitive and Memory Enhancer Drugs Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Johnson & Johnson Cognitive and Memory Enhancer Drugs Product Portfolio
  24. 8.4.5 Johnson & Johnson Recent Developments
  25. 8.5 Novartis
  26. 8.5.1 Novartis Company Information
  27. 8.5.2 Novartis Business Overview
  28. 8.5.3 Novartis Cognitive and Memory Enhancer Drugs Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Novartis Cognitive and Memory Enhancer Drugs Product Portfolio
  30. 8.5.5 Novartis Recent Developments
  31. 8.6 Pfizer
  32. 8.6.1 Pfizer Company Information
  33. 8.6.2 Pfizer Business Overview
  34. 8.6.3 Pfizer Cognitive and Memory Enhancer Drugs Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Pfizer Cognitive and Memory Enhancer Drugs Product Portfolio
  36. 8.6.5 Pfizer Recent Developments
  37. 8.7 Ceretropic
  38. 8.7.1 Ceretropic Company Information
  39. 8.7.2 Ceretropic Business Overview
  40. 8.7.3 Ceretropic Cognitive and Memory Enhancer Drugs Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Ceretropic Cognitive and Memory Enhancer Drugs Product Portfolio
  42. 8.7.5 Ceretropic Recent Developments
  43. 8.8 Cephalon
  44. 8.8.1 Cephalon Company Information
  45. 8.8.2 Cephalon Business Overview
  46. 8.8.3 Cephalon Cognitive and Memory Enhancer Drugs Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Cephalon Cognitive and Memory Enhancer Drugs Product Portfolio
  48. 8.8.5 Cephalon Recent Developments
  49. 8.9 AlternaScript
  50. 8.9.1 AlternaScript Company Information
  51. 8.9.2 AlternaScript Business Overview
  52. 8.9.3 AlternaScript Cognitive and Memory Enhancer Drugs Revenue and Gross Margin (2021-2026)
  53. 8.9.4 AlternaScript Cognitive and Memory Enhancer Drugs Product Portfolio
  54. 8.9.5 AlternaScript Recent Developments
  55. 8.10 Allergan
  56. 8.10.1 Allergan Company Information
  57. 8.10.2 Allergan Business Overview
  58. 8.10.3 Allergan Cognitive and Memory Enhancer Drugs Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Allergan Cognitive and Memory Enhancer Drugs Product Portfolio
  60. 8.10.5 Allergan Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst